HORSHAM, PA — NMS Labs has appointed Tatyana Kosheleva as Chief Financial Officer, effective April 28, 2025. This leadership move underscores the company’s commitment to operational excellence and long-term growth.
With over 20 years of global financial expertise in the pharmaceutical, medical device, and technology sectors, Kosheleva has a proven track record in developing financial infrastructure, enhancing internal controls, and driving strategic acquisitions. She previously served as CFO of Nordic Pharma, Inc., where she played a pivotal role in finance and commercialization initiatives.
“Tatyana is a proven finance leader with deep expertise in building strong, scalable organizations,” said Dave Delia, Chief Executive Officer of NMS Labs. “Her appointment, along with other recent changes to our leadership team, positions us for our next chapter of growth and impact.”
This appointment is part of a larger effort to strengthen NMS Labs’ leadership. The company also recently named Dan Reed as Chief Operating Officer and Marianne Jackson as Chief Commercial Officer, all aimed at enhancing operations, client services, and market expansion.
Kosheleva’s extensive experience includes roles at Ferring Pharmaceuticals, DST Global Solutions, OppenheimerFunds, and IBM. She also serves as Finance Chair for the Drug Information Association and holds CPA certification.
NMS Labs’ leadership evolution reflects its focus on innovation, financial stewardship, and delivering exceptional value to its clients.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.